effect
liposomeencapsul
immunomodul
antivir
activ
ifn
evalu
studi
immunomodul
activ
measur
increas
phagocyt
activ
nitric
oxid
product
periton
macrophag
mice
treat
free
umous
intraperiton
inject
resid
periton
macrophag
harvest
mice
treat
free
unencapsul
muramyl
dipeptid
show
signific
increas
macrophag
yield
enhanc
abil
phagocyt
zymosan
particl
mice
treat
liposomeencapsul
macrophag
yield
phagocyt
activ
increas
unencapsul
addit
activ
periton
macrophag
show
enhanc
product
cell
cultur
ex
vivo
use
murin
respiratori
influenza
infect
model
intranas
administ
lipifn
confer
protect
mice
challeng
intranas
dose
influenza
viru
compar
surviv
rate
use
free
togeth
result
suggest
liposomeencapsul
increas
immunomodul
antivir
activ
liposomeencapsul
may
provid
addit
therapeut
advantag
reduc
toxic
prolong
bodi
retent
virusinfect
cell
antivir
activ
believ
mediat
bind
specif
receptor
turn
induc
product
number
transient
protein
known
inhibit
viru
replic
joklik
pinto
et
al
also
import
regul
number
immunolog
function
increas
express
major
histocompat
antigen
regul
product
antibodi
blymphocyt
joklik
stimul
macrophag
function
increas
macrophag
product
hydrogen
peroxid
joklik
thu
activ
macrophag
may
play
import
role
abil
destroy
invad
microorgan
particularli
infecti
virus
parasit
recent
interferon
demonstr
stimul
product
reactiv
nitrogen
intermedi
particular
nitric
oxid
mediat
intracellular
kill
wide
rang
host
respons
fortier
et
al
green
naci
zhang
et
al
includ
inhibit
viral
replic
karupiah
et
al
characterist
make
promis
broadspectrum
therapeut
agent
prevent
treatment
infecti
diseas
howev
therapeut
potenti
antimicrobi
immunomodul
agent
limit
partial
effect
vivo
known
toxic
cardiac
renal
cn
function
joklik
quesada
et
al
addit
small
protein
ifn
administ
bodi
like
subject
immedi
dilut
rapid
clearanc
bodi
may
reach
target
cell
bino
et
al
gutterman
et
al
kurzrock
et
al
problem
potenti
overcom
use
liposom
deliveri
system
liposom
microscop
lipid
vesicl
number
characterist
make
attract
drug
deliveri
system
variou
antimicrobi
immunomodul
agent
post
et
al
gregoriadi
wong
et
al
therapeut
agent
encapsul
within
liposom
protect
vivo
degrad
dilut
post
et
al
wong
et
al
encapsul
drug
readili
releas
liposom
gradual
sustain
manner
thu
increas
prophylactictherapeut
efficaci
reduc
intrins
toxic
post
et
al
post
et
al
petenazzo
et
al
liposom
particularli
well
suit
carrier
macrophag
stimul
agent
sinc
readili
taken
macrophag
upon
system
pulmonari
periton
administr
agent
deliv
macrophag
concentr
level
post
et
al
post
et
al
without
advers
affect
healthi
nontarget
cell
inde
liposomeencapsul
shown
number
investig
effect
free
ifn
treatment
number
experiment
infect
includ
bacteri
listeria
monocytogen
melissen
et
al
klebsiella
pneumonia
ten
hagen
et
al
protozo
leishmania
donovani
hockertz
et
al
potenti
efficaci
viral
infect
howev
remain
unexploit
addit
effect
liposomeencapsul
intrins
immunomodul
effect
ifn
studi
extens
purpos
present
studi
evalu
effect
liposom
deliveri
system
potenti
antivir
well
immunomodulatori
activ
ifn
specif
modul
cellmedi
immun
free
liposomeencapsul
ifn
determin
increas
macrophag
activ
measur
increas
phagocyt
activ
product
antivir
activ
assess
vivo
efficaci
lipifn
protect
mice
lethal
respiratori
influenza
infect
approach
use
deliveri
system
ifnr
may
provid
use
mean
enhanc
host
defenc
resist
respiratori
viru
infect
potenti
decreas
inher
toxic
associ
use
interferon
sixweekold
femal
balbc
mice
purchas
charl
river
canada
st
constant
que
mice
acclim
week
vivarium
use
care
handl
anim
follow
guidelin
set
canadian
council
anim
care
recombin
mous
purchas
boehring
mannheim
canada
dorval
que
phosphatidylcholin
phosphatidylserin
cholesterol
use
prepar
liposom
avanti
polar
lipid
alabast
al
liposom
use
studi
encapsul
prepar
use
modif
freezedri
method
describ
kirbi
gregoriadi
negativelycharg
liposom
prepar
use
phosphatidylcholinecholesterolphosphatidylserin
molar
ratio
briefli
total
lipid
chloroformmethanol
vv
dri
heat
throughout
procedur
content
tube
purg
gentl
stream
dri
nitrogen
lipid
dri
min
vacuum
oven
remov
residu
organ
solvent
lipid
rehydr
ml
mm
hepe
buffer
normal
salin
ph
hepe
buffer
ad
lipid
mixtur
freezedri
overnight
total
volum
ktl
uml
mixtur
reconstitut
tl
hepe
buffer
vortex
min
reconstitut
liposom
left
rehydr
h
room
temperatur
wash
twice
ml
hepe
buffer
ultracentrifug
x
g
min
incub
room
temperatur
h
ultracentrifug
liposom
pellet
resuspend
ml
hepe
buffer
prior
use
liposom
neg
stain
sodium
phosphotungst
ph
morpholog
vesicl
size
distribut
analyz
electron
microscopi
multilamellar
vesicl
mlv
prepar
use
method
found
heterogen
size
vesicl
diamet
rang
approxim
nm
tm
equival
lipid
contain
u
control
mice
inject
pb
ip
h
postinject
macrophag
harvest
mice
use
modif
periton
lavag
procedur
describ
mischel
shiigi
lavag
fluid
use
periton
wash
ml
contain
ml
rpmi
ml
fetal
bovin
serum
fb
flow
laboratori
mississauga
ont
g
sodium
chlorid
harvest
cell
wash
rpmi
fb
solut
filter
steril
tm
nalgen
filter
nalg
compani
rochest
ny
store
recov
lavag
fluid
ml
lavag
mous
pool
centrifug
x
g
min
result
cell
pellet
wash
rpmi
plu
fb
flow
laboratori
rockvil
md
resuspend
final
volum
ml
buffer
cell
suspens
layer
onto
ml
histopaqu
sigma
centrifug
x
g
min
macrophag
collect
aspir
cell
densiti
gradient
interfac
use
pasteur
pipet
cell
suspend
rpmi
final
volum
ml
centrifug
z
g
min
red
blood
cell
remov
pellet
lysi
deioniz
water
min
cell
suspend
rpmi
centrifug
pellet
resuspend
ml
rpmi
viabl
cell
count
trypan
blue
dye
exclus
isol
cell
visual
identifi
macrophag
slide
prepar
centrifug
ml
purifi
sampl
onto
glass
slide
use
cytospin
centrifug
shandon
southern
product
ltd
astmoor
uk
slide
left
dri
overnight
prepar
stain
stat
stain
vwr
scientif
inc
brisban
ca
sampl
examin
microscop
use
oil
immers
x
magnif
balbc
femal
mice
intraperiton
ip
inject
singl
dose
muramyl
dipeptid
mdp
mgml
pb
sigma
chemic
co
st
loui
mo
free
ifni
uml
mole
phagocyt
activ
periton
macrophag
determin
chemiluminesc
wherebi
phagocytosi
zymosan
particl
macrophag
presenc
lucigenin
result
emiss
light
measur
luminomet
assay
macrophag
concentr
x
cellsml
rpmi
use
assay
phagocyt
activ
chemiluminesc
luminomet
cuvett
fill
ktl
cell
plu
tl
lucigenin
sigma
place
lkb
luminomet
lkb
stockholm
sweden
luminometercontrol
dispens
deliv
rpmi
human
serum
activ
zymosan
sampl
time
zero
assay
total
chemiluminesc
measur
mv
record
period
min
interv
sampl
h
macrophag
activ
also
measur
function
nitric
oxid
releas
periton
macrophag
measur
form
oxid
product
nitrit
ion
group
five
mice
administ
two
daili
dose
u
free
day
postadministr
periton
macrophag
treat
control
mice
harvest
periton
lavag
describ
incub
addit
day
phenol
redfre
medium
phenol
redfre
medium
use
rpmi
sigma
supplement
fetal
bovin
serum
mm
lglutamin
penicillin
g
u
ml
streptomycin
sulphat
zgml
amphotericin
b
zgml
gibco
laboratori
grand
island
ny
sodium
bicarbon
gibco
resid
periton
cell
resuspend
cell
per
ml
ml
phenol
redfre
rpmi
incub
h
atmospher
aliquot
cultur
supernat
assay
nitric
oxid
releas
function
nitrit
concentr
solut
previous
report
green
et
al
ding
et
al
protect
influenza
viru
infect
evalu
use
intranas
administr
free
liposomeencapsul
influenza
viru
adapt
mice
four
blind
passag
use
eggpropag
viru
describ
previous
wong
et
al
volum
intranas
administr
intranas
administr
mice
anesthet
sodium
pentobarbitol
mgkg
ip
anim
unconsci
care
support
hand
nose
materi
administ
gentli
appli
micropipetor
nostril
appli
volum
natur
inhal
lung
group
sodium
pentobarbitolanesthet
mice
mice
per
group
inocul
intranas
either
u
per
mous
tmol
total
lipid
contain
u
per
mous
sham
liposom
sham
lip
amol
total
lipid
per
mous
mice
pretreat
interv
begin
either
day
intranas
challeng
mouseadapt
influenza
viru
day
postviru
challeng
number
mice
surviv
viru
challeng
record
statist
analysi
data
carri
use
student
ttest
analysi
perform
use
sigmaplot
softwar
program
jandel
scientif
san
rafael
ca
averag
yield
macrophag
control
mice
treat
mdp
shown
tabl
treatment
mdp
increas
macrophag
yield
compar
control
untreat
group
highest
macrophag
yield
found
mice
treat
increas
yield
compar
control
group
phagocyt
activ
periton
macrophag
measur
chemiluminesc
assay
macrophag
isol
mice
treat
singl
dose
demonstr
increas
phagocyt
activ
earli
h
administr
phagocyt
activ
highest
h
postadministr
h
decreas
near
level
h
fig
phagocyt
activ
macrophag
measur
chemiluminesc
found
highest
mice
treat
fig
peak
level
phagocyt
activ
lipifni
treat
group
found
approxim
higher
pb
control
group
higher
sham
liposom
group
higher
group
statist
signific
p
assess
effect
lipifni
product
activ
macrophag
tissu
cultur
supernat
activ
macrophag
incub
day
assay
presenc
nitrit
ion
data
fig
demonstr
small
statist
signific
increas
nitrit
level
macrophag
group
compar
pb
control
group
p
contrast
tissu
cultur
supernat
macrophag
treat
lipifni
level
nitrit
found
significantli
increas
compar
either
pb
control
group
p
periton
macrophag
harvest
suspend
describ
section
incub
overnight
nitrit
releas
cell
supernat
measur
use
griess
reagent
p
experi
carri
two
time
sham
liposom
free
variou
interv
prior
intranas
infect
ldso
influenza
summar
tabl
group
mice
pretreat
either
pb
sham
liposom
complet
unprotect
infect
influenza
viru
mean
death
time
day
treat
unencapsul
small
surviv
rate
group
mice
repeat
dose
prior
viral
inocul
mice
pretreat
highest
surviv
rate
singl
dose
effect
dose
repeat
intranas
dose
lipifni
day
prior
infect
influenza
viru
result
surviv
rate
effect
administ
three
dose
interv
prior
infect
influenza
result
surviv
rate
tabl
mean
death
time
day
increas
dose
liposom
u
u
per
dose
result
signific
increas
surviv
rate
result
shown
abil
ifn
protect
mice
influenza
viru
infect
compar
determin
liposom
encapsul
increas
efficaci
antivir
activ
group
mice
pretreat
either
pb
efficaci
interferon
prevent
respiratori
viru
infect
evalu
rhinoviru
coronaviru
hayden
gwaltney
higgin
et
al
dougla
et
al
tabl
efficaci
intranas
administ
protect
mice
infect
ldso
mouseadapt
influenza
viru
group
day
infect
survivor
surviv
mean
day
death
pb
sham
lip
l
l
p
p
vs
group
experi
carri
twiceados
use
per
mous
sham
lip
pmole
lipid
equival
liposom
u
pmole
lipid
equival
liposom
contain
u
ifni
monto
et
al
may
consid
use
prevent
respiratori
influenza
infect
sinc
provok
antivir
immunomodul
respons
suscept
host
howev
one
major
drawback
interferon
therapi
interferon
toxic
molecul
caus
sever
toxic
central
nervou
system
renal
cardiac
function
quesada
et
al
joklik
although
effect
liposomeencapsul
ifnv
toxic
determin
present
studi
hockertz
et
al
demonstr
toxic
effect
seen
mice
inject
necrot
lesion
loss
bodi
weight
mhc
class
ii
express
absent
mice
treat
dose
encapsul
liposom
therefor
liposomeencapsul
may
prove
extrem
valuabl
interferon
immunotherapi
liposom
potenti
significantli
reduc
interferon
toxic
slow
releas
characterist
addit
target
ifn
liposom
specif
infect
site
may
therefor
avoid
caus
toxic
effect
nontarget
cell
organ
hockertz
et
al
melissen
et
al
liposom
use
studi
encapsul
negativelycharg
multilamellar
vesicl
liposom
type
shown
number
investig
effici
taken
macrophag
positivelycharg
unilamellar
vesicl
post
et
al
post
et
al
freezedri
method
use
product
liposom
rel
mild
method
requir
expos
organ
solvent
sonic
deterg
method
previous
demonstr
suitabl
encapsul
number
biolog
activ
compound
post
et
al
wong
et
al
wong
et
al
administ
mice
appear
act
chemotact
agent
phagocyt
cell
result
increas
accumul
periton
macrophag
comparison
placebotr
control
chemotact
natur
observ
may
entir
part
due
liposom
effect
sinc
sham
liposom
also
result
increas
accumul
periton
macrophag
although
increas
macrophag
accumul
due
sham
liposom
result
increas
protect
viral
infect
vivo
chemotact
natur
present
effect
mechan
deliveri
wherebi
encapsul
ifni
may
releas
gradual
liposom
close
proxim
congreg
macrophag
multilamellar
liposom
shown
natur
taken
pulmonari
macrophag
via
phagocytosi
fidler
et
al
fidler
uptak
lipinfi
macrophag
report
allow
bind
intracellular
receptor
macrophag
fidler
et
al
addit
ifn
may
exert
antivir
effect
target
cell
lung
via
receptorindepend
deliveri
ifn
provid
liposom
deliveri
killion
fidler
report
bonemarrowderiv
macrophag
expos
presenc
phagocyt
stimulu
protozoan
parasit
latex
bead
found
produc
elev
level
nitrit
wherea
stimulu
absent
nitrit
produc
corradin
et
al
find
alon
induc
nitrit
product
periton
macrophag
appear
consist
observ
howev
administ
liposom
form
signific
level
nitrit
produc
liposom
may
therefor
provid
type
phagocyt
stimulu
previous
observ
stimul
product
sinc
liposom
readili
taken
macrophag
may
directli
releas
liposom
intracellular
compart
howev
phagocyt
rout
entri
may
also
result
lysosom
degrad
liposom
well
overcom
potenti
problem
investig
feasibl
develop
fusogen
liposom
capabl
fuse
directli
membran
target
cell
thu
permit
content
liposom
deliv
intracellularli
bypass
degrad
phagocyt
process
nayar
schroit
present
studi
demonstr
efficaci
protect
infect
influenza
viru
significantli
enhanc
liposorneencapsul
protect
influenza
mortal
could
observ
mice
pretreat
free
major
advantag
approach
singl
dose
provid
level
protect
mice
dose
three
day
pretreat
result
surviv
infect
mice
compar
treat
mice
increas
efficaci
may
also
result
increas
retent
ifn
lung
afford
liposom
encapsul
inde
radiotrac
studi
use
indic
lung
retent
liposomeencapsul
igg
unencapsul
igg
even
h
postadministr
wong
et
al
observ
decreas
surviv
day
pretreat
may
reflect
rel
narrow
optimum
dose
rang
merigan
administr
lipifn
host
significantli
delay
onset
morbid
mortal
associ
viral
diseas
liposomeencapsul
result
increas
nonspecif
cellmedi
immun
increas
surviv
lethal
dose
influenza
major
benefit
form
treatment
gradual
releas
liposom
allow
host
immun
system
time
elicit
natur
specif
immun
respons
fight
infect
addit
abil
augment
product
mous
macrophag
may
play
import
role
enhanc
bodi
defenc
mechan
fight
viral
infect
effector
molecul
produc
variou
mammalian
cell
type
includ
macrophag
oxid
intermedi
nitrit
nitrat
known
play
import
role
cellmedi
kill
wide
rang
pathogen
microorgan
includ
virus
karupiah
et
al
present
studi
demonstr
liposomeencapsul
significantli
affect
antivir
immunomodul
activ
liposom
deliveri
found
enhanc
nonspecif
activ
macrophag
result
increas
phagocyt
activ
product
efficaci
protect
mice
lethal
respiratori
infect
influenza
viru
also
significantli
improv
liposomeencapsul
immunolog
therapeut
advantag
combin
potenti
liposom
deliveri
significantli
reduc
intrins
toxic
may
therefor
provid
valuabl
benefici
approach
clinic
use
antivir
immunotherapi
